FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952394893> ?p ?o ?g. }

• W2952394893 endingPage "753" @default.
• W2952394893 startingPage "753" @default.
• W2952394893 abstract "Background: Patients suffering with chronic kidney disease (CKD) commonly present with anemia. Current treatment regimens consist of iron, erythropoietin stimulating agents (ESAs), or both, but a significant number of patients remain anemic despite these therapies. Hepcidin, a liver-derived hormone, is a central regulator of iron homeostasis, frequently elevated in CKD patients and thought to represent a root cause of the hypoferremia. Therefore, hepcidin inhibition has the potential to ameliorate functional iron deficiency anemia in CKD patients. PRS-080 is a pegylated Anticalin® hepcidin protein antagonist that has been shown to induce dose dependent serum iron mobilization and increased transferrin saturation (TSAT) in single ascending dose phase 1 clinical studies, both in healthy male volunteers and dialysis dependent CKD patients (PLOS-One, in press). Aims: To determine the safety and tolerability of 5 repeated intravenous administrations of PRS-080 at doses of 4 and 8 mg/kg body weight (BW) compared to placebo, in anemic, hemodialysis dependent stage 5 CKD patients, as well as to assess pharmacokinetics, pharmacodynamics and immunogenicity. Methods: Twelve patients were enrolled. Four patients per cohort each received PRS-080 at a dose of 4 or 8 mg/kg, with two patients per cohort receiving placebo. The study included a screening period of 4 weeks; the mean of 3 hemoglobin (Hb) values during the screening period, each obtained at least 7 days apart, was required to be ≤10.5 g/dL with a difference of ≤1.0 g/dL between the lowest and highest values. Additional inclusion criteria included Ferritin > 300 ng/mL and TSAT ≤30%. The ESA dose had to remain stable for at least 4 weeks prior to screening, as well as through the treatment period, and iron therapy had to be withdrawn 1 week before randomization. Study medication was administered by infusion over 60 minutes using an infusion pump on day 0, day 7, day 14, day 21, and day 28. Patients were observed with regard to safety up until day 112. Safety was monitored continuously by a data safety monitoring board (DSMB), including prior to dose escalation. Results: There were no treatment related adverse events (AEs) or serious adverse events (SAEs). Robust iron mobilization with increases in both serum iron and TSAT were consistently observed following each weekly dose in both dose cohorts. Peak iron concentrations were higher in the 8 mg/kg cohort than in the 4 mg/kg cohort. Whereas there was no clear difference in Hb values between placebo and PRS-080 patients in the 4 mg/kg cohort over the course of treatment, evidence of a Hb response with clear separation of Hb values between placebo and PRS-080 could be shown in the 8 mg/kg cohort during the treatment period, consisting of an increase of Hg in drug treated patients and a decline in placebo patients, potentially related to the withdrawal of iron treatment. Summary/Conclusion: PRS-080 was safe and well tolerated at both dose levels in this exploratory phase 2a multiple ascending dose clinical study in anemic dialysis-dependent CKD patients. Promising results were achieved in terms of both iron mobilization and increased TSAT, as well as initial evidence of an increase in Hb levels in the higher dose group. Further studies to determine the optimal treatment regimen with PRS-080 are warranted." @default.
• W2952394893 created "2019-06-27" @default.
• W2952394893 creator A5002398588 @default.
• W2952394893 creator A5003755692 @default.
• W2952394893 creator A5005201489 @default.
• W2952394893 creator A5008432515 @default.
• W2952394893 creator A5015430004 @default.
• W2952394893 creator A5035017368 @default.
• W2952394893 creator A5035952474 @default.
• W2952394893 creator A5049125906 @default.
• W2952394893 creator A5054252836 @default.
• W2952394893 creator A5060068748 @default.
• W2952394893 creator A5074560478 @default.
• W2952394893 creator A5082465033 @default.
• W2952394893 creator A5091647539 @default.
• W2952394893 date "2019-06-01" @default.
• W2952394893 modified "2023-10-05" @default.
• W2952394893 title "S1630 A PHASE IIA STUDY TO EVALUATE THE SAFETY, PK AND PD OF REPEATED ADMINISTRATIONS OF THE HEPCIDIN ANTAGONIST PRS-080 IN ANEMIC CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HEMODIALYSIS" @default.
• W2952394893 doi "https://doi.org/10.1097/01.hs9.0000564768.07487.e5" @default.
• W2952394893 hasPublicationYear "2019" @default.
• W2952394893 type Work @default.
• W2952394893 sameAs 2952394893 @default.
• W2952394893 citedByCount "1" @default.
• W2952394893 countsByYear W29523948932020 @default.
• W2952394893 crossrefType "journal-article" @default.
• W2952394893 hasAuthorship W2952394893A5002398588 @default.
• W2952394893 hasAuthorship W2952394893A5003755692 @default.
• W2952394893 hasAuthorship W2952394893A5005201489 @default.
• W2952394893 hasAuthorship W2952394893A5008432515 @default.
• W2952394893 hasAuthorship W2952394893A5015430004 @default.
• W2952394893 hasAuthorship W2952394893A5035017368 @default.
• W2952394893 hasAuthorship W2952394893A5035952474 @default.
• W2952394893 hasAuthorship W2952394893A5049125906 @default.
• W2952394893 hasAuthorship W2952394893A5054252836 @default.
• W2952394893 hasAuthorship W2952394893A5060068748 @default.
• W2952394893 hasAuthorship W2952394893A5074560478 @default.
• W2952394893 hasAuthorship W2952394893A5082465033 @default.
• W2952394893 hasAuthorship W2952394893A5091647539 @default.
• W2952394893 hasBestOaLocation W29523948931 @default.
• W2952394893 hasConcept C126322002 @default.
• W2952394893 hasConcept C134018914 @default.
• W2952394893 hasConcept C142724271 @default.
• W2952394893 hasConcept C153852466 @default.
• W2952394893 hasConcept C197934379 @default.
• W2952394893 hasConcept C204787440 @default.
• W2952394893 hasConcept C27081682 @default.
• W2952394893 hasConcept C2776710925 @default.
• W2952394893 hasConcept C2776768029 @default.
• W2952394893 hasConcept C2777417653 @default.
• W2952394893 hasConcept C2778063415 @default.
• W2952394893 hasConcept C2778248108 @default.
• W2952394893 hasConcept C2778319317 @default.
• W2952394893 hasConcept C2778375690 @default.
• W2952394893 hasConcept C2778653478 @default.
• W2952394893 hasConcept C2779875672 @default.
• W2952394893 hasConcept C2779978075 @default.
• W2952394893 hasConcept C71924100 @default.
• W2952394893 hasConcept C90924648 @default.
• W2952394893 hasConceptScore W2952394893C126322002 @default.
• W2952394893 hasConceptScore W2952394893C134018914 @default.
• W2952394893 hasConceptScore W2952394893C142724271 @default.
• W2952394893 hasConceptScore W2952394893C153852466 @default.
• W2952394893 hasConceptScore W2952394893C197934379 @default.
• W2952394893 hasConceptScore W2952394893C204787440 @default.
• W2952394893 hasConceptScore W2952394893C27081682 @default.
• W2952394893 hasConceptScore W2952394893C2776710925 @default.
• W2952394893 hasConceptScore W2952394893C2776768029 @default.
• W2952394893 hasConceptScore W2952394893C2777417653 @default.
• W2952394893 hasConceptScore W2952394893C2778063415 @default.
• W2952394893 hasConceptScore W2952394893C2778248108 @default.
• W2952394893 hasConceptScore W2952394893C2778319317 @default.
• W2952394893 hasConceptScore W2952394893C2778375690 @default.
• W2952394893 hasConceptScore W2952394893C2778653478 @default.
• W2952394893 hasConceptScore W2952394893C2779875672 @default.
• W2952394893 hasConceptScore W2952394893C2779978075 @default.
• W2952394893 hasConceptScore W2952394893C71924100 @default.
• W2952394893 hasConceptScore W2952394893C90924648 @default.
• W2952394893 hasIssue "S1" @default.
• W2952394893 hasLocation W29523948931 @default.
• W2952394893 hasLocation W29523948932 @default.
• W2952394893 hasOpenAccess W2952394893 @default.
• W2952394893 hasPrimaryLocation W29523948931 @default.
• W2952394893 hasRelatedWork W1976899832 @default.
• W2952394893 hasRelatedWork W2054827204 @default.
• W2952394893 hasRelatedWork W2070785335 @default.
• W2952394893 hasRelatedWork W2089715210 @default.
• W2952394893 hasRelatedWork W2495495877 @default.
• W2952394893 hasRelatedWork W2794141976 @default.
• W2952394893 hasRelatedWork W2940533351 @default.
• W2952394893 hasRelatedWork W3017171205 @default.
• W2952394893 hasRelatedWork W4205593170 @default.
• W2952394893 hasRelatedWork W4248614430 @default.
• W2952394893 hasVolume "3" @default.
• W2952394893 isParatext "false" @default.
• W2952394893 isRetracted "false" @default.
• W2952394893 magId "2952394893" @default.
• W2952394893 workType "article" @default.